Literature DB >> 32361816

The epidemiology of aggressive pituitary tumors (and its challenges).

Olaf M Dekkers1,2,3, Niki Karavitaki4,5,6, Alberto M Pereira7,8.   

Abstract

Pituitary tumors are not rare if prevalence rates from autopsy or radiological series are considered; approximately 0.5% of all pituitary adenomas will come to medical attention. Less than 0.1% of these pituitary adenomas will become malignant, and probably around 0.5% of all detected adenomas will display an aggressive course. However, the exact incidence of both aggressive pituitary adenomas and pituitary carcinomas is unknown, as most data come from series with selected patients, such as surgically treated patients, which is likely not a reflection of all patients with a pituitary adenoma. An aggressive pituitary adenoma is not well-defined; even though an overarching definition, capturing both immunohistochemical and clinical characteristics is probably not waterproof, adoption of a widely accepted definition will be very helpful to harmonize research and establish more reliable epidemiological data.

Entities:  

Keywords:  Aggressive pituitary adenoma; Carcinoma; Epidemiology; Incidence

Year:  2020        PMID: 32361816     DOI: 10.1007/s11154-020-09556-7

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  7 in total

Review 1.  Aggressive pituitary tumours and pituitary carcinomas.

Authors:  Gérald Raverot; Mirela Diana Ilie; Hélène Lasolle; Vincent Amodru; Jacqueline Trouillas; Frédéric Castinetti; Thierry Brue
Journal:  Nat Rev Endocrinol       Date:  2021-09-07       Impact factor: 43.330

2.  A Convolutional Neural Network Model for Detecting Sellar Floor Destruction of Pituitary Adenoma on Magnetic Resonance Imaging Scans.

Authors:  Tianshun Feng; Yi Fang; Zhijie Pei; Ziqi Li; Hongjie Chen; Pengwei Hou; Liangfeng Wei; Renzhi Wang; Shousen Wang
Journal:  Front Neurosci       Date:  2022-07-04       Impact factor: 5.152

3.  Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?

Authors:  Ken Ho; Maria Fleseriu; Ursula Kaiser; Roberto Salvatori; Thierry Brue; M Beatriz Lopes; Pamela Kunz; Mark Molitch; Sally A Camper; Mônica Gadelha; Luis V Syro; Edward Laws; Martin Reincke; Hiroshi Nishioka; Ashley Grossman; Ariel Barkan; Felipe Casanueva; John Wass; Adam Mamelak; Laurence Katznelson; Aart J van der Lely; Sally Radovick; Martin Bidlingmaier; Margaret Boguszewski; Jens Bollerslev; Andrew R Hoffman; Nelson Oyesiku; Gerald Raverot; Anat Ben-Shlomo; Rob Fowkes; Ilan Shimon; Hidenori Fukuoka; Alberto M Pereira; Yona Greenman; Anthony P Heaney; Mark Gurnell; Gudmundur Johannsson; Robert Y Osamura; Michael Buchfelder; Maria Chiara Zatelli; Marta Korbonits; Philippe Chanson; Nienke Biermasz; David R Clemmons; Niki Karavitaki; Marcello D Bronstein; Peter Trainer; Shlomo Melmed
Journal:  J Endocr Soc       Date:  2021-02-09

4.  Association of PTTG1 expression with invasiveness of non-functioning pituitary adenomas.

Authors:  Su Jung Kum; Hye Won Lee; Soon Gu Kim; Hyungsik Park; Ilseon Hwang; Sang Pyo Kim
Journal:  J Pathol Transl Med       Date:  2021-10-15

5.  Chemotherapy of Capecitabine plus Temozolomide for Refractory Pituitary Adenoma after Tumor Resection and Its Impact on Serum Prolactin, IGF-1, and Growth Hormone.

Authors:  Xirui Wang; Changwei Hu; Yabin Li; Baowen Ren; Gangfeng Yin
Journal:  J Oncol       Date:  2022-03-21       Impact factor: 4.375

Review 6.  Aggressive corticotroph tumors and carcinomas.

Authors:  Hélène Lasolle; Alexandre Vasiljevic; Emmanuel Jouanneau; Mirela Diana Ilie; Gérald Raverot
Journal:  J Neuroendocrinol       Date:  2022-08-18       Impact factor: 3.870

7.  Outcome of giant pituitary tumors requiring surgery.

Authors:  Stephan Gaillard; Sosthène Adeniran; Chiara Villa; Anne Jouinot; Marie-Laure Raffin-Sanson; Loic Feuvret; Pierre Verrelle; Fidéline Bonnet; Anthony Dohan; Jérôme Bertherat; Guillaume Assié; Bertrand Baussart
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.